On Monday, SpringWorks Therapeutics (SWTX) stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 86, up from 77 the day before.
↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate CutsThis proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
SpringWorks Therapeutics stock is working on a cup without handle with a 53.92 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.
The biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 0%.
SpringWorks Therapeutics stock holds the No. 46 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.